KAPSPARGO SPRINKLE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for KAPSPARGO SPRINKLE (KAPSPARGO SPRINKLE).
Sodium-glucose cotransporter-2 (SGLT2) inhibitor; reduces glucose reabsorption in renal proximal tubules, increasing urinary glucose excretion and lowering blood glucose.
| Metabolism | Primarily metabolized via uridine diphosphate-glucuronosyltransferase (UGT) enzymes (UGT1A9, UGT2B7), forming inactive glucuronides; minimal CYP450 involvement. |
| Excretion | Primarily renal excretion as unchanged drug (40-50%) and metabolites; fecal elimination accounts for <5%. |
| Half-life | Terminal elimination half-life is 11-13 hours in healthy adults, 17-19 hours in elderly patients; clinically relevant for once-daily dosing. |
| Protein binding | 99% bound, primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd is 1.3-2.4 L/kg, indicating extensive extravascular distribution. |
| Bioavailability | Oral sprinkle: 60-70% (absolute bioavailability). |
| Onset of Action | Oral (sprinkle): 30-60 minutes after administration. |
| Duration of Action | Approximately 12-24 hours; clinical effect persists with consistent dosing. |
5 mg to 25 mg per day administered orally. For children below 80 kg, starting dose is 0.2 mg per kg per day. Maximum dose is 25 mg per day.
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | For GFR 30 to 60 mL/min: reduce dose by 50%. For GFR less than 30 mL/min: contraindicated. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: not recommended. |
| Pediatric use | For children 1 to 17 years: initial dose 0.2 mg per kg per day, up to 10 mg per day. Titrate based on response, maximum 25 mg per day. |
| Geriatric use | For patients 65 years or older: start at 5 mg per day, titrate slowly with careful monitoring for electrolyte disturbances. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for KAPSPARGO SPRINKLE (KAPSPARGO SPRINKLE).
| Breastfeeding | No human data on secretion in breast milk. M/P ratio unknown. Phenylbutyrate is small molecule likely excreted; taurursodiol has high protein binding possibly limiting transfer. Caution advised; weigh benefits of breastfeeding against potential infant exposure. |
| Teratogenic Risk | KAPSPARGO SPRINKLE (sodium phenylbutyrate and taurursodiol) is not associated with increased risk of major congenital malformations based on limited human data. First trimester: theoretical risk due to phenylbutyrate's histone deacetylase inhibition; animal studies show fetal toxicity at high doses. Second/third trimester: potential for fetal growth restriction and preterm birth. Overall, benefit may outweigh risk in ALS. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Severe renal impairment (eGFR < 30 mL/min/1.73 m2)","End-stage renal disease or dialysis","History of serious hypersensitivity reaction to canagliflozin","Type 1 diabetes (not indicated)"]
| Precautions | ["Risk of volume depletion, hypotension, and renal impairment","Ketoacidosis in patients with type 1 diabetes or pancreatic insufficiency","Necrotizing fasciitis of the perineum (Fournier gangrene)","Increased LDL cholesterol","Genital mycotic infections","Urinary tract infections"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal liver function tests, serum ammonia, electrolytes, and renal function. Fetal monitoring with ultrasound for growth and amniotic fluid volume. Consider non-stress test in third trimester. |
| Fertility Effects | No human studies. In animal studies, sodium phenylbutyrate affected estrous cycle and fertility at high doses. Taurursodiol showed no adverse fertility effects. Clinical relevance unknown; advise counseling regarding potential reversible fertility impairment. |